However, a phase II clinical trial in patients with advanced STS, SARC028, showed that only ~17.5% of patients responded to anti–PD-1 monotherapy, which suggests that sarcomas are more resistant to immune checkpoint blockade compared with 40%–45% objective response rates in patients with melanoma and NSCLC (4). This evidence concerns the gene PDCD1 and sarcoma.